NCT01935817

Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: University of Catania · Academic / Other
• Sex: All
• Age: 40 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Chronic hepatitis C is both a virologic and a fibrotic disease, with mortality resulting mainly from the complications of cirrhosis and HCC. The investigators' aim will be to evaluate the impact on of supplementation with a new pharmaceutical complex of silybin-vitamin E-phospholipids in patients with chronic hepatitis C treated with Pegylated-Interferon-α2b plus Ribavirin.

Conditions

• Liver Fibrosis

Interventions

Type	Name	Description
DRUG	Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex
DRUG	Placebo

Timeline

• Start date: 2010-06-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2013-09-05
• Last updated: 2013-09-05

Locations

1 site across 1 country: Italy